Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson Progress
0% Complete
Foundational Principles and Risk Assessment of Enterocutaneous and Enteroatmospheric Fistulas

Foundational Principles and Risk Assessment of Enterocutaneous and Enteroatmospheric Fistulas

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Learning Objective

Describe the foundational principles of enterocutaneous (ECF) and enteroatmospheric fistulas (EAF), including pathophysiology, clinical presentation, and risk factors.

1. Clinical Relevance and Impact

Enterocutaneous (ECF) and enteroatmospheric fistulas (EAF) are devastating complications in critically ill surgical and trauma patients. They drive sepsis, malnutrition, prolonged ICU stays, and significant resource utilization.

Morbidity and Mortality

  • EAF mortality can be as high as 40%.
  • ECF mortality ranges from 10–30% in ICU cohorts.

Resource Implications

  • Prolonged ICU and hospital length of stay.
  • High‐cost parenteral nutrition.
  • Complex wound care requirements.
  • Need for repeated interventions.

Under-recognition

Non‐surgical ICUs often miss early signs such as skin excoriation or subtle fluid losses from wound sites.

Clinical Presentation

  • Local: Erythema, excoriation, and maceration around a stoma or open abdominal wound.
  • Systemic: Systemic Inflammatory Response Syndrome (SIRS), sepsis, hemodynamic instability.
  • Laboratory: Hyponatremia, hypokalemia, hypomagnesemia, metabolic acidosis, hypoalbuminemia.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Vigilance for Occult Fistulas

In any ICU patient with unexplained fluid losses or refractory sepsis, meticulously inspect surgical wounds or open abdomen sites for occult fistula output. Early multidisciplinary consultation involving surgery, nutrition, wound care, and pharmacy is essential for optimal management.

2. Epidemiology

The incidence of ECF and EAF varies significantly depending on the type of surgical procedure, the context of trauma, and institutional practices. Awareness of high‐risk settings is crucial for guiding surveillance and early detection.

A. Surgical ICU Incidence

  • Procedure‐specific rates: Colorectal surgery (2–5%), gastric or small‐bowel resections (1–3%), re‐exploration for anastomotic leak (10–15%).
  • Iatrogenic causes: Approximately 75–85% of ECFs occur postoperatively.
  • Prevention strategies: Preoperative nutritional repletion, meticulous surgical technique, and judicious use of drains can mitigate risk.

B. Trauma ICU Incidence

  • Open abdomen techniques: Used for damage control surgery, these techniques are associated with an EAF incidence of 2–25%. This risk increases with prolonged duration of the open abdomen and repeated re‐explorations.
  • Timing: Fistulas typically appear 7–14 days post‐injury or surgery, coinciding with the peak inflammatory response.
Controversy Icon A chat bubble with a question mark, indicating a point of controversy or debate. Controversy: Standardization of Reporting

The lack of standardized reporting criteria for ECF and EAF leads to wide variations in reported incidence rates across different centers. Harmonized definitions and reporting standards are urgently needed for accurate benchmarking, comparative research, and the development of targeted prevention strategies.

3. Pathophysiology

Fistula formation originates from a disruption of the intestinal barrier, which leads to the development of abnormal tracts, uncontrolled loss of effluent, bacterial translocation, and systemic inflammation.

A. Intestinal Barrier Disruption

  • Triggers: Surgical injury (e.g., inadvertent enterotomy, anastomotic leak), ischemia (often related to vasopressor use or hypoperfusion states), inflammation (as seen in Inflammatory Bowel Disease or intra‐abdominal sepsis), and tissue damage from radiation or chemotherapy.
  • Histopathology: The process typically begins with mucosal necrosis, followed by the formation of a tract. This tract may eventually become epithelialized, which can impede spontaneous closure.
Triggering Event
(Surgery, Ischemia)
Intestinal Barrier
Disruption
Tract
Formation
Effluent Loss &
Bacterial Translocation
Systemic Inflammation
& Malnutrition
Figure 1: Pathophysiological Cascade of Fistula Development. This diagram illustrates the sequence of events starting from an initial insult, leading to disruption of the intestinal wall, formation of a fistulous tract, and subsequent local and systemic consequences.

B. Effluent Loss and Systemic Effects

  • Fluid and electrolyte losses: High‐output fistulas (defined as >500 mL/day) can lead to significant hypovolemia, hyponatremia, hypokalemia, hypomagnesemia, and metabolic acidosis.
  • Protein losses: Substantial protein loss through fistula effluent contributes to hypoalbuminemia and a negative nitrogen balance, impairing healing.
  • Bacterial translocation: The compromised intestinal barrier allows bacteria and their toxins to enter the systemic circulation, increasing the risk of SIRS and sepsis.
  • Catabolism: The combination of inflammation, infection, and malnutrition promotes a catabolic state, further worsening tissue healing and predisposing to multi‐organ dysfunction.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Location and Output Volume

The anatomical location of the fistula (proximal vs. distal small bowel, colon) and the volume of its output are the primary predictors of metabolic derangement severity and the likelihood of spontaneous closure. Proximal, high‐output fistulas are particularly challenging and rarely close without surgical intervention.

4. Chronic Disease Impact

Pre‐existing comorbidities can significantly weaken tissue integrity, alter the clinical presentation of fistulas, and worsen overall outcomes in affected patients.

  • Inflammatory Bowel Disease (IBD): The transmural inflammation characteristic of Crohn’s disease predisposes patients to both spontaneous fistula formation and postoperative fistulization.
  • Radiation Enteritis/Chemotherapy: Chronic tissue fibrosis and impaired epithelial regeneration resulting from radiation therapy or chemotherapy increase the risk of spontaneous or iatrogenic fistulas.
  • Diabetes Mellitus/Vascular Disease: These conditions are associated with microvascular compromise, impaired leukocyte function, and delayed wound healing, all of which can complicate fistula management.
  • Chronic Kidney Disease/Malignancy: Patients with these conditions often exhibit a pro‐inflammatory state, malnutrition, and immunosuppression, creating a challenging environment for fistula healing.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Comorbidities and Management

Patients with multiple comorbidities require aggressive risk stratification and highly individualized management plans. These plans should focus on optimizing nutrition, rigorously controlling infection, and enhancing the patient’s intrinsic healing potential to improve fistula outcomes.

5. Social Determinants of Health

Socioeconomic and system‐level factors critically modify the risk, recognition, and management of enterocutaneous and enteroatmospheric fistulas. These determinants can significantly impact patient outcomes.

  • Medication access/adherence: Financial constraints or insurance barriers can undermine adherence to perioperative prophylactic regimens and essential postoperative care, including medications for output control or nutritional support.
  • Health literacy: Poor understanding of medical conditions or treatment plans can lead to delays in reporting critical symptoms, such as new drainage, skin changes around a wound, or signs of infection.
  • Socioeconomic status: Factors such as transportation difficulties, housing instability, and lack of adequate caregiver support can profoundly affect a patient’s ability to attend outpatient follow‐up appointments and manage complex wound care at home.
  • System‐level barriers: Fragmented care coordination between different providers or healthcare settings, limited availability of home health resources, and inadequate transitions of care can compromise the continuity and effectiveness of fistula management.
Controversy Icon A chat bubble with a question mark, indicating a point of controversy or debate. Controversy: Integrating Social Determinants into Risk Assessment

Despite the clear influence of social determinants on fistula outcomes, there is a lack of validated tools to systematically integrate these factors into routine risk assessments and clinical care pathways. Developing and implementing such tools is crucial for equitable care.

6. Clinical Decision Points and Controversies

Effective management of ECF and EAF requires a careful balance between timely intervention and the risk of premature surgery, which can worsen outcomes. The integration of clinical, anatomical, metabolic, and social risk factors is key to guiding resource allocation and therapeutic strategies.

  • Risk‐stratification tools: Existing scoring systems primarily focus on fistula output volume and anatomical characteristics. However, they often omit crucial factors like social determinants of health and the impact of comorbidities, limiting their comprehensive predictive value.
  • Multidisciplinary teams: Early collaboration among specialists—including surgery, critical care, nutrition, wound care, pharmacy, and social work—is widely recognized to improve outcomes. However, the optimal structure and operational models for these teams remain undefined and may vary by institutional context.
  • Timing of surgery: A significant point of debate involves the optimal timing for definitive surgical closure. Generally, a delayed approach (≥6 weeks) is favored to allow for sepsis control and nutritional optimization. However, early surgical intervention may be considered in select cases, such as those with complete bowel discontinuity or minimal contamination.
  • Output reduction therapies: The routine use of somatostatin analogs (e.g., octreotide) to reduce fistula output remains a subject of controversy. Some advocate for their routine use in high-output fistulas, while others prefer a more selective or “rescue” approach when conservative measures fail.
Pearl Icon A shield with an exclamation mark, indicating a clinical pearl. Clinical Pearl: Holistic Risk Assessment for Triage

Incorporate a comprehensive assessment of clinical, anatomical, metabolic, and social risk factors at the initial evaluation of a patient with an ECF or EAF. This holistic approach is crucial for effectively triaging patients towards conservative versus operative management strategies and for allocating supportive care resources appropriately.

References

  1. Ghimire P, Shrestha S, Khadka S, Thapa N, Karki S, Ghimire S. Management of Enterocutaneous Fistula: A Review. J Nepal Med Assoc. 2022;60(245):93–100.
  2. Pepe G, Magalini S, La Greca A, et al. Entero-Cutaneous and Entero-Atmospheric Fistulas: Insights into Management Using Negative Pressure Wound Therapy. J Clin Med. 2024;13(5):1279.
  3. Gribovskaja-Rupp I, Melton GB. Enterocutaneous Fistula: Proven Strategies and Updates. Clin Colon Rectal Surg. 2016;29(2):130–137.
  4. Haack CI, Gips K, Guller U, SAGES ECF Task Force, Horber F, Slawik M. Enterocutaneous Fistulas: Causes and Management. Curr Surg Rep. 2014;2(10):71.
  5. Fischer JE. The Pathophysiology of Enterocutaneous Fistulas. World J Surg. 1983;7(4):446–450.
  6. Coccolini F, Ceresoli M, Kluger Y, et al. Open Abdomen and Entero-Atmospheric Fistulae: Interim Analysis from IROA. Injury. 2019;50(1):160–166.
  7. Wainstein DE, Fernandez Vila JM, Gonzalez D, McWay R, Palavezzati M, Oria A. Management of Enteroatmospheric Fistula: A Ten-Year Experience. Surgery. 2023;173(4):1079–1085.
  8. Klek S, Forbes A, Gabe S, et al. Management of Acute Intestinal Failure: ESPEN Position Paper. Clin Nutr. 2016;35(6):1209–1218.